• Explore /
  • Poster
  • / A novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma (RRMM): Updated phase 1b results for daratumumab in combination with teclistamab (a BCMA x CD3 bispecific antibody).

A novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma (RRMM): Updated phase 1b results for daratumumab in combination with teclistamab (a BCMA x CD3 bispecific antibody).

Abstract Video & Slides Poster

Authors

Paula Rodríguez-Otero

Paula Rodríguez-Otero

Clínica Universidad de Navarra, Madrid, Spain

Paula Rodríguez-Otero , Anita D'Souza , Donna Ellen Reece , Niels W.C.J. van de Donk , Ajai Chari , Amrita Y. Krishnan , Thomas G. Martin , Maria-Victoria Mateos , Daniel Morillo , David Duane Hurd , Laura Rosiñol , Anna Sureda Balari , Ralph Wäsch , Deeksha Vishwamitra , Shun Xin Wang Lin , Thomas Prior , Lien Vandenberk , Marie-Anne Damiette Smit , Albert Oriol Rocafiguera , Bhagirathbhai R. Dholaria

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT04108195

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 8032)

DOI

10.1200/JCO.2022.40.16_suppl.8032

Abstract #

8032

Poster Bd #

456

Abstract Disclosures

Similar Posters

First Author: Cesar Rodriguez Valdes

First Author: Robert M. Rifkin

First Author: Shaji Kumar

First Author: Sagar Lonial